Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Interventistico
Fase 2
West China Hospital of Sichuan University
Sponsor: Zelgen Biopharmaceuticals
Ultimo Aggiornamento: 25 marzo 2025 Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Categoria di Trattamento
Altri Farmaci, Anticorpi Monoclonali, Inibitori dei Checkpoint